The connection between autism spectrum disorder and Parkinson's disease risk may have identifiable neurological signatures decades before movement symptoms appear. This discovery could reshape how clinicians monitor brain health in autistic individuals throughout their lifespan. Researchers used specialized brain imaging to examine dopamine transporter function in 18-24-year-old adults with autism spectrum disorder. The dopamine transporter, a protein that regulates dopamine levels in brain circuits, showed definite or possible abnormalities in one-third of participants. Those with abnormal dopamine transporter patterns displayed altered connectivity between the striatum—a brain region central to movement and reward processing—and the paracingulate cortex, an area involved in cognitive control and attention. This finding provides the first direct neuroimaging evidence linking dopamine system dysfunction in young autistic adults to the established six-fold increased Parkinson's disease risk observed in this population. The research addresses a critical gap in understanding how brain aging differs in autism. Current autism medications primarily target dopamine receptors to manage behavioral symptoms, but this study suggests the transport mechanism itself may be compromised. The small sample size of 12 participants limits generalizability, and the clinical significance of these brain changes remains unclear. However, the work establishes proof-of-concept for using dopamine transporter imaging as a potential biomarker. If replicated in larger studies, this approach could enable early identification of autistic individuals at heightened neurodegeneration risk, potentially allowing for preventive interventions decades before traditional Parkinson's symptoms emerge.